asymmetric dimethylarginine ADMA
Selected indexed studies
- Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA). (Toxins (Basel), 2017) [PMID:28272322]
- Effect of asymmetric dimethylarginine (ADMA) on heart failure development. (Nitric Oxide, 2016) [PMID:26923818]
- Asymmetric Dimethylarginine (ADMA): a promising biomarker for cardiovascular disease? (Curr Top Med Chem, 2013) [PMID:23470077]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA). (2017) pubmed
- Effect of asymmetric dimethylarginine (ADMA) on heart failure development. (2016) pubmed
- Asymmetric Dimethylarginine (ADMA): a promising biomarker for cardiovascular disease? (2013) pubmed
- Metabolite asymmetric dimethylarginine (ADMA) functions as a destabilization enhancer of SOX9 mediated by DDAH1 in osteoarthritis. (2023) pubmed
- Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease. (2018) pubmed
- Asymmetric dimethylarginine (ADMA) modulates endothelial function--therapeutic implications. (2003) pubmed
- Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease. (2015) pubmed
- Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. (2006) pubmed
- Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. (2009) pubmed
- Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? (2002) pubmed